NFKB1 -94ins/del ATTG polymorphism increases osteosarcoma risk in a Chinese Han population

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 1, 2015, Pages 1420-1423

  Li, Xiyi ^a,b,c   Zhang, Chenglin ^c   Qiao, Wei ^a,b   Zhou, Xuhui ^c   Sun, Menghong ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Genetics; Nuclear factor B; Osteosarcoma; Polymorphism

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADULT; ALLELE; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE DELETION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOSARCOMA;

EID: 84922980806     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer 2009; 125: 229-34.
2. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemio0logy, and End Results Program. Cancer 2009; 115: 1531-43.
3. Caamaño J, Hunter CA. NF-kappaB family of transcription factors: central regulators of innate and adaptive immune functions. Clin Microbiol Rev 2002; 15: 414-29.
4. Huang TT, Kudo N, Yoshida M, Miyamoto S. A nuclear export signal in the N-terminal regulatory domain of IkappaBalpha controls cytoplasmic localization of inactive NF-kappaB/IkappaBalpha complexes. Proc Natl Acad Sci U S A 2000; 97: 1014-9.
5. Sun XF, Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol 2007; 22: 1387-98.
6. Karban AS, Okazaki T, Panhuysen CI, Gallegos T, Potter JJ, Bailey-Wilson JE, Silverberg MS, Duerr RH, Cho JH, Gregersen PK, Wu Y, Achkar JP, Dassopoulos T, Mezey E, Bayless TM, Nouvet FJ, Brant SR. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 2004; 13: 35-45.
7. Mohd Suzairi MS, Tan SC, Ahmad Aizat AA, Mohd Aminudin M, Siti Nurfatimah MS, Andee ZD, Ankathil R. The functional -94 insertion/deletion ATTG polymorphism in the promoter region of NFKB1 gene increases the risk of sporadic colorectal cancer. Cancer Epidemiol 2013; 37: 634-8.
8. Shiels MS, Engels EA, Shi J, Landi MT, Albanes D, Chatterjee N, Chanock SJ, Caporaso NE, Chaturvedi AK. Genetic variation in innate immunity and inflammation pathways associated with lung cancer risk. Cancer 2012; 118: 5630-6.
9. Cheng CW, Su JL, Lin CW, Su CW, Shih CH, Yang SF, Chien MH. Effects of NFKB1 and NFKBIA gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathological features. PLoS One 2013; 8: e56130.
10. Curran JE, Weinstein SR, Griffiths LR. Poly-morphic variants of NFKB1 and its inhibitory protein NFKBIA, and their involvement in sporadic breast cancer. Cancer Lett 2002; 188: 103-7.
11. Zhang Y, Hu X, Wang HK, Shen WW, Liao TQ, Chen P, Chu TW. Single-nucleotide polymorphisms of the PRKCG gene and osteosarcoma susceptibility. Tumour Biol 2014; 35: 12671-7.
12. Zhao J, Xu H, He M, Wang Z, Wu Y. Rho GTPase-activating protein 35 rs1052667 polymorphism and osteosarcoma risk and prognosis. Biomed Res Int 2014; 2014: 396947.
13. Jiang C, Chen H, Shao L, Dong Y. GRM4 gene polymorphism is associated with susceptibility and prognosis of osteosarcoma in a Chinese Han population. Med Oncol 2014; 31: 50.
14. Lv H, Pei J, Liu H, Wang H, Liu J. A polymorphism site in the pre-miR-34a coding region reduces miR-34a expression and promotes osteosarcoma cell proliferation and migration. Mol Med Rep 2014; 10: 2912-6.
15. Dong-Ju Z, Ai-Ju X, Yun-Jiao T, Ming-Qiu Z. Polymorphisms of vascular endothelial growth factor on prognosis in osteosarcoma patients. Pak J Med Sci 2014; 30: 1072-6.
16. Duan W, Wang E, Zhang F, Wang T, You X, Qiao B. Association between the NFKB1-94ins/del ATTG polymorphism and cancer risk: an updated meta-analysis. Cancer Invest 2014; 32: 311-20.